Cargando…

A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin

BACKGROUND: The protein neutrophil gelatinase-associated lipocalin (NGAL) is a mediator synthesized and released by neutrophils. Its physiological function is as yet unclear. Levels in blood increase in several inflammatory diseases. High serum values indicate poor prognosis for several diseases. Pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gümüs, Aziz, Ozkaya, Sevket, Ozyurt, Songul, Cınarka, Halit, Kirbas, Aynur, Sahin, Unal, Ece, Ferah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169811/
https://www.ncbi.nlm.nih.gov/pubmed/25243068
http://dx.doi.org/10.1186/2049-6958-9-49
_version_ 1782335765788753920
author Gümüs, Aziz
Ozkaya, Sevket
Ozyurt, Songul
Cınarka, Halit
Kirbas, Aynur
Sahin, Unal
Ece, Ferah
author_facet Gümüs, Aziz
Ozkaya, Sevket
Ozyurt, Songul
Cınarka, Halit
Kirbas, Aynur
Sahin, Unal
Ece, Ferah
author_sort Gümüs, Aziz
collection PubMed
description BACKGROUND: The protein neutrophil gelatinase-associated lipocalin (NGAL) is a mediator synthesized and released by neutrophils. Its physiological function is as yet unclear. Levels in blood increase in several inflammatory diseases. High serum values indicate poor prognosis for several diseases. Pleural effusion may appear as the result of various pathologies. The most common cause is heart failure (HF). Other common causes include parapneumonic (PPE) and malignant (MPE) pleural effusions, and pulmonary embolism. Tubercular effusion (TE) is commonly encountered in Turkey and similar developing countries. The purpose of this study was to investigate the effectiveness of NGAL, a current inflammation marker, in discriminating between different etiological diseases that cause pleural effusion. METHODS: The study was performed at the Recep Tayyip Erdoğan University Faculty of Medicine Chest Diseases Clinic. One hundred patients were included in the study, 25 with parapneumonic effusion, 25 with heart failure-related effusion, 25 with tubercular effusion and 25 with cancer-related effusion. NGAL was measured in patients’ serum and pleural fluids. RESULTS: Serum NGAL levels in PPE (171 ± 56 ng/ml) were significantly higher (p < 0.001) than those in HF (86 ± 31 ng/ml), CA (103 ± 42 ng/ml) and TE (63 ± 19 ng/ml). Pleural NGAL levels were also significantly higher in PPE compared to HF, MPE and TE (p < 0.001). Serum NGAL levels exhibited a positive correlation with white blood cell (WBC), neutrophil, C-reactive protein (CRP), sedimentation, serum LDH, creatinine, pleural leukocyte and pleural neutrophil numbers. The most significant correlation was between NGAL level and WBC (p < 0.001, r = 0.579). Both serum and pleural NGAL levels are highly effective in differentiating patients with PPE from those without PPE (AUC: 0.910 and 0.790, respectively). CONCLUSIONS: NGAL can be used in the diagnosis of diseases with an acute inflammatory course. Serum and pleural NGAL levels can differentiate PPE from other diseases causing pleural fluid with high sensitivity and specificity.
format Online
Article
Text
id pubmed-4169811
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41698112014-09-22 A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin Gümüs, Aziz Ozkaya, Sevket Ozyurt, Songul Cınarka, Halit Kirbas, Aynur Sahin, Unal Ece, Ferah Multidiscip Respir Med Original Research Article BACKGROUND: The protein neutrophil gelatinase-associated lipocalin (NGAL) is a mediator synthesized and released by neutrophils. Its physiological function is as yet unclear. Levels in blood increase in several inflammatory diseases. High serum values indicate poor prognosis for several diseases. Pleural effusion may appear as the result of various pathologies. The most common cause is heart failure (HF). Other common causes include parapneumonic (PPE) and malignant (MPE) pleural effusions, and pulmonary embolism. Tubercular effusion (TE) is commonly encountered in Turkey and similar developing countries. The purpose of this study was to investigate the effectiveness of NGAL, a current inflammation marker, in discriminating between different etiological diseases that cause pleural effusion. METHODS: The study was performed at the Recep Tayyip Erdoğan University Faculty of Medicine Chest Diseases Clinic. One hundred patients were included in the study, 25 with parapneumonic effusion, 25 with heart failure-related effusion, 25 with tubercular effusion and 25 with cancer-related effusion. NGAL was measured in patients’ serum and pleural fluids. RESULTS: Serum NGAL levels in PPE (171 ± 56 ng/ml) were significantly higher (p < 0.001) than those in HF (86 ± 31 ng/ml), CA (103 ± 42 ng/ml) and TE (63 ± 19 ng/ml). Pleural NGAL levels were also significantly higher in PPE compared to HF, MPE and TE (p < 0.001). Serum NGAL levels exhibited a positive correlation with white blood cell (WBC), neutrophil, C-reactive protein (CRP), sedimentation, serum LDH, creatinine, pleural leukocyte and pleural neutrophil numbers. The most significant correlation was between NGAL level and WBC (p < 0.001, r = 0.579). Both serum and pleural NGAL levels are highly effective in differentiating patients with PPE from those without PPE (AUC: 0.910 and 0.790, respectively). CONCLUSIONS: NGAL can be used in the diagnosis of diseases with an acute inflammatory course. Serum and pleural NGAL levels can differentiate PPE from other diseases causing pleural fluid with high sensitivity and specificity. BioMed Central 2014-09-15 /pmc/articles/PMC4169811/ /pubmed/25243068 http://dx.doi.org/10.1186/2049-6958-9-49 Text en © Gümüs et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Research Article
Gümüs, Aziz
Ozkaya, Sevket
Ozyurt, Songul
Cınarka, Halit
Kirbas, Aynur
Sahin, Unal
Ece, Ferah
A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
title A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
title_full A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
title_fullStr A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
title_full_unstemmed A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
title_short A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
title_sort novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169811/
https://www.ncbi.nlm.nih.gov/pubmed/25243068
http://dx.doi.org/10.1186/2049-6958-9-49
work_keys_str_mv AT gumusaziz anovelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT ozkayasevket anovelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT ozyurtsongul anovelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT cınarkahalit anovelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT kirbasaynur anovelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT sahinunal anovelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT eceferah anovelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT gumusaziz novelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT ozkayasevket novelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT ozyurtsongul novelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT cınarkahalit novelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT kirbasaynur novelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT sahinunal novelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin
AT eceferah novelbiomarkerinthediagnosisofparapneumoniceffusionneutrophilgelatinaseassociatedlipocalin